137 related articles for article (PubMed ID: 15535307)
1. [Treatment of platinum-resistant ovarian cancer].
Onishi Y; Nakamura T; Hatae M
Nihon Rinsho; 2004 Oct; 62 Suppl 10():554-9. PubMed ID: 15535307
[No Abstract] [Full Text] [Related]
2. [Second-line chemotherapy for recurrent ovarian cancer].
Sugiyama T
Gan To Kagaku Ryoho; 2005 Jan; 32(1):28-32. PubMed ID: 15675578
[TBL] [Abstract][Full Text] [Related]
3. Topotecan in platinum- and paclitaxel-resistant ovarian cancer.
Swisher EM; Mutch DG; Rader JS; Elbendary A; Herzog TJ
Gynecol Oncol; 1997 Sep; 66(3):480-6. PubMed ID: 9299264
[TBL] [Abstract][Full Text] [Related]
4. New options for the treatment of advanced ovarian cancer.
Dunton CJ
Semin Oncol; 1997 Feb; 24(1 Suppl 5):S5-2-S5-11. PubMed ID: 9122739
[TBL] [Abstract][Full Text] [Related]
5. Weekly docetaxel for patients with platinum/paclitaxel/irinotecan-resistant relapsed ovarian cancer: a phase I study.
Terauchi F; Hirano T; Taoka H; Masaki K; Yamamoto Y; Ogura H; Kubo H
Int J Clin Oncol; 2003 Dec; 8(6):348-51. PubMed ID: 14663635
[TBL] [Abstract][Full Text] [Related]
6. Improved survival trends in platinum-resistant patients with advanced ovarian, fallopian or peritoneal cancer treated with first-line paclitaxel/platinum chemotherapy: the impact of novel agents.
Bamias A; Bamia C; Zagouri F; Kostouros E; Kakoyianni K; Rodolakis A; Vlahos G; Haidopoulos D; Thomakos N; Antsaklis A; Dimopoulos MA
Oncology; 2013; 84(3):158-65. PubMed ID: 23296063
[TBL] [Abstract][Full Text] [Related]
7. Bevacizumab Combined With Weekly Paclitaxel, Pegylated Liposomal Doxorubicin, or Topotecan in Platinum-Resistant Recurrent Ovarian Cancer: Analysis by Chemotherapy Cohort of the Randomized Phase III AURELIA Trial.
Poveda AM; Selle F; Hilpert F; Reuss A; Savarese A; Vergote I; Witteveen P; Bamias A; Scotto N; Mitchell L; Pujade-Lauraine E
J Clin Oncol; 2015 Nov; 33(32):3836-8. PubMed ID: 26282651
[No Abstract] [Full Text] [Related]
8. [Ovarian cancer treatment from the standpoint of the gynecologic oncologist].
Sugiyama T; Yoshizaki A; Hatayama S
Gan To Kagaku Ryoho; 2007 Jul; 34(7):1011-6. PubMed ID: 17637537
[TBL] [Abstract][Full Text] [Related]
9. Docetaxel in combination with irinotecan (CPT-11) in platinum-resistant paclitaxel-pretreated ovarian cancer.
Polyzos A; Kosmas C; Toufexi H; Malamos N; Lagadas A; Kosmidis C; Ginopoulos P; Ziras N; Kandilis K; Georgoulias V
Anticancer Res; 2005; 25(5):3559-64. PubMed ID: 16101180
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and toxicity of belotecan with and without cisplatin in patients with recurrent ovarian cancer.
Nam EJ; Kim JW; Kim JH; Kim S; Kim SW; Jang SY; Lee DW; Jung YW; Kim YT
Am J Clin Oncol; 2010 Jun; 33(3):233-7. PubMed ID: 19745693
[TBL] [Abstract][Full Text] [Related]
11. Successful analysis of anticancer drug sensitivity by CD-DST using pleural fluid and ascites from patients with advanced ovarian cancer: case reports.
Kawaguchi M; Banno K; Susumu N; Yanokura M; Kuwabara Y; Hirao N; Tsukazaki K; Nozawa S
Anticancer Res; 2005; 25(5):3547-51. PubMed ID: 16101178
[TBL] [Abstract][Full Text] [Related]
12. The activity of taxanes compared with bleomycin, etoposide, and cisplatin in the treatment of sex cord-stromal ovarian tumors.
Brown J; Shvartsman HS; Deavers MT; Ramondetta LM; Burke TW; Munsell MF; Gershenson DM
Gynecol Oncol; 2005 May; 97(2):489-96. PubMed ID: 15863149
[TBL] [Abstract][Full Text] [Related]
13. [New treatment strategy for stage III non-small-cell lung cancer].
Yoh K; Kubota K
Nihon Rinsho; 2002 May; 60 Suppl 5():485-9. PubMed ID: 12101719
[No Abstract] [Full Text] [Related]
14. Improving the toxicity profile of chemotherapy for advanced ovarian cancer: a potential role for CT-2103.
Markman M
J Exp Ther Oncol; 2004 Jul; 4(2):131-6. PubMed ID: 15500007
[TBL] [Abstract][Full Text] [Related]
15. Correlation between extreme drug resistance assay and response to primary paclitaxel and cisplatin in patients with epithelial ovarian cancer.
Nagourney RA
Gynecol Oncol; 2000 Jan; 76(1):143. PubMed ID: 10620464
[No Abstract] [Full Text] [Related]
16. Chemotherapy for ovarian cancer: an evidence-based approach.
Geisler JP; Manahan KJ; Wiemann MC
Minerva Ginecol; 2004 Dec; 56(6):539-45. PubMed ID: 15729206
[TBL] [Abstract][Full Text] [Related]
17. [A case of platinum-resistant, recurrent ovarian clear cell adenocarcinoma successfully treated with irinotecan (CPT-11) and paclitaxel (PTX) chemotherapy].
Konishi H; Takehara K; Okame S; Yamamoto Y; Kojima A; Shiroyama Y; Yokoyama T; Nogawa T
Gan To Kagaku Ryoho; 2014 Nov; 41(11):1437-9. PubMed ID: 25434451
[TBL] [Abstract][Full Text] [Related]
18. [Therapy for ovarian cancer--general review].
Ochiai K
Nihon Rinsho; 2004 Oct; 62 Suppl 10():517-21. PubMed ID: 15535299
[No Abstract] [Full Text] [Related]
19. Phase I/IIa study of combination chemotherapy with CKD-602 and cisplatin in patients with recurrent epithelial ovarian cancer.
Kim HS; Kang SB; Seo SS; Han SS; Kim JW; Park NH; Kang SB; Lee HP; Song YS
Ann N Y Acad Sci; 2009 Aug; 1171():627-34. PubMed ID: 19723113
[TBL] [Abstract][Full Text] [Related]
20. [New regimens for the treatment of gynecologic cancers].
Sugiyama T; Ushijima K; Kamura T
Gan To Kagaku Ryoho; 2000 Mar; 27(3):375-81. PubMed ID: 10740630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
